COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04641481 Bharat Biotech Ella R, Lancet, 2021 b Full text Commentary |
Inactivated virus |
BBV152 |
Adjuvant |
RCTPhase 3 | Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India | N= 25798 |
Some concerns Details |
|
|
NCT04471519 Bharat Biotech Ella R, Lancet Infect Dis, 2021 a Updated Full text Commentary |
Inactivated virus |
2 dose 3mcg BBV152 nCoV-19 vaccine + Algel-IMDG adjuvant, Days 0/14, 0.5mL 2 dose 6mcg BBV152 nCoV-19 vaccine + Algel-IMDG adjuvant, Days 0/14, 0.5mL 2 dose 6mcg BBV152 nCoV-19 vaccine + Algel adjuvant, Days 0/14, 0.5mL |
Adjuvant (Algel) |
RCTPhase 1 | Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India | N= 375 |
Some concerns Details |
|